ORN-0829 HYDRATE

Summary

Orn-0829 Hydrate (CHEMBL4650522) is a phase-3 clinical-stage unknown; indicated across 3 conditions including insomnia and obstructive sleep apnea syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650522
Name	ORN-0829 HYDRATE
Type	Unknown
Max phase	3

Also known as: Orn-0829 hydrate, ORN-0829 HYDRATE, ORN0829 HYDRATE, Ts-142

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
insomnia	3	MONDO:0013600	EFO:0004698
obstructive sleep apnea syndrome	1	MONDO:0007147	EFO:0003918
liver disorder	1	MONDO:0005154	EFO:0001421

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE1	11
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05453136	PHASE3	COMPLETED	Phase III Study of TS-142 in Patients with Insomnia
NCT05461352	PHASE3	COMPLETED	Long-Term Study of TS-142 in Patients with Insomnia
NCT04469023	PHASE2	COMPLETED	Late Phase II Study of TS-142 in Patients with Insomnia
NCT04573725	PHASE2	COMPLETED	Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder
NCT04169893	PHASE1	COMPLETED	A Phase I Study of TS-142 in Healthy Participants (Single Doses)
NCT04169906	PHASE1	COMPLETED	A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)
NCT04464239	PHASE1	COMPLETED	A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants
NCT04557163	PHASE1	COMPLETED	Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)
NCT04696952	PHASE1	COMPLETED	A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects
NCT04746105	PHASE1	COMPLETED	A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.
NCT04814771	PHASE1	COMPLETED	Mass Balance Study of TS-142 in Healthy Adult Subjects.
NCT04873323	PHASE1	COMPLETED	A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects
NCT05624944	PHASE1	COMPLETED	A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
NCT05707897	PHASE1	COMPLETED	A Food Effect Study of TS-142 in Healthy Subjects
NCT05819710	PHASE1	COMPLETED	A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).